Monte Rosa Therapeutics Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.